WT1 and cancer: Our previous study has found that YPFS could regulate p62/TRAF6 signaling (Lou et al., 2016), WT1/MVP axis and mTORC2/AKT signaling (Lou et al., 2018), which account the anti-MDR effects and anti-cancer effects both in vivo and in vitro models.